相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes
Lingxu Jiang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
Acquired somatic variants in inherited myeloid malignancies
Hannah Armes et al.
LEUKEMIA (2022)
Myelodysplastic Syndromes: A New Decade
Virginia O. Volpe et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes
Nehakumari Maurya et al.
SCIENTIFIC REPORTS (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
GATA 2 Deficiency: Focus on Immune System Impairment
Francesco Fabozzi et al.
FRONTIERS IN IMMUNOLOGY (2022)
The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications
Hee Sue Park et al.
ANNALS OF HEMATOLOGY (2022)
Diagnosis and Treatment of Myelodysplastic Syndromes A Review
Mikkael A. Sekeres et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
Razan Mohty et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms
Yudi Zhang et al.
LEUKEMIA (2022)
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose- escalation, dose-expansion, phase 1-2 study
Alexandre Bazinet et al.
LANCET HAEMATOLOGY (2022)
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes
Junying Wu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)
Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment
Fabiana Kalina Marques et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?
Emilia Scalzulli et al.
BLOOD REVIEWS (2021)
Gene mutation spectrum of patients with myelodysplastic syndrome and progression to acute myeloid leukemia
Ming Liu et al.
International Journal of Hematologic Oncology (2021)
Current and emerging strategies for management of myelodysplastic syndromes
Caner Saygin et al.
BLOOD REVIEWS (2021)
CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM
Pierre Peterlin et al.
BLOOD (2021)
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes
Aziz Nazha et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
Alessandro Liquori et al.
CANCERS (2021)
Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome
Paul Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia
Shyam A. Patel et al.
LEUKEMIA & LYMPHOMA (2021)
The Genetics of Myelodysplastic Syndromes: Clinical Relevance
Chiara Chiereghin et al.
GENES (2021)
Transcription Factors, R-Loops and Deubiquitinating Enzymes: Emerging Targets in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Silvia M. L. Barabino et al.
CANCERS (2021)
Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a grey zone combination of myelodysplastic and myeloproliferative features?
Valentina F. I. Sangiorgio et al.
HAEMATOLOGICA (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation
Marie Anne Hospital et al.
CURRENT ONCOLOGY REPORTS (2020)
Genetics of progression from MDS to secondary leukemia
Andrew J. Menssen et al.
BLOOD (2020)
Myelodysplastic syndromes: moving towards personalized management
Eva Hellstrom-Lindberg et al.
HAEMATOLOGICA (2020)
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Guillermo Garcia-Manero et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis
Jili Deng et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms
Justin Taylor et al.
BLOOD (2020)
AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances
Kristin L. Koenig et al.
GENES (2020)
Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges
Gabriel C. Caponetti et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
Brian J. Ball et al.
BLOOD ADVANCES (2020)
Prognostic Markers of Myelodysplastic Syndromes
Yuliya Andreevna Veryaskina et al.
MEDICINA-LITHUANIA (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome
Haiqiong Wang et al.
SCIENTIFIC REPORTS (2020)
The Molecular Pathology of Myelodysplastic Syndrome
Torsten Haferlach
PATHOBIOLOGY (2019)
Genetic abnormalities and pathophysiology of MDS
Naoko Hosono
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
What role can next-generation sequencing play in myelodysplastic syndrome care?
Nicolas Bonadies et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
The functional mechanisms of mutations in myelodysplastic syndrome
Yasunobu Nagata et al.
LEUKEMIA (2019)
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
David A. Sallman et al.
BLOOD (2019)
Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms
Qi Zhang et al.
GENES & DISEASES (2019)
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy
Guillermo Montalban-Bravo et al.
BLOOD ADVANCES (2019)
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Laurence Lode et al.
HAEMATOLOGICA (2018)
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Laurence Lode et al.
HAEMATOLOGICA (2018)
Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
The genetic and molecular pathogenesis of myelodysplastic syndromes
Rory M. Shallis et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes
Peipei Lin et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome
Hsin-An Hou et al.
BLOOD CANCER JOURNAL (2018)
Dynamics of clonal evolution in myelodysplastic syndromes
Hideki Makishima et al.
NATURE GENETICS (2017)
Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
Manja Meggendorfer et al.
HAEMATOLOGICA (2017)
Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies
Jing-dong Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
The clonal origins of leukemic progression of myelodysplasia
T. Kim et al.
LEUKEMIA (2017)
Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide
Satoko Oka et al.
LEUKEMIA & LYMPHOMA (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing
Yuanyuan Xu et al.
ONCOTARGET (2017)
Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS
Aziz Nazha et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
Manja Meggendorfer et al.
HAEMATOLOGICA (2017)
Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes
Feng Xu et al.
SCIENTIFIC REPORTS (2017)
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Adam S. Sperling et al.
NATURE REVIEWS CANCER (2017)
Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Implications of molecular genetic diversity in myelodysplastic syndromes
Rafael Bejar
CURRENT OPINION IN HEMATOLOGY (2017)
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
A. Toma et al.
LEUKEMIA (2016)
Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression
A. Pellagatti et al.
LEUKEMIA (2016)
Myelodysplastic syndrome with del (5q) and JAK2V617F mutation transformed to acute myeloid leukaemia with complex karyotype
Achille Pich et al.
ANNALS OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
M. Mossner et al.
LEUKEMIA (2016)
Mutations of myelodysplastic syndromes (MDS): An update
Bani Bandana Ganguly et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2016)
Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy
Chunli Dan et al.
ANNALS OF MEDICINE (2015)
Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia
Manja Meggendorfer et al.
HAEMATOLOGICA (2015)
Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology
Young-Uk Cho et al.
LEUKEMIA & LYMPHOMA (2015)
NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
Fabio Forghieri et al.
LEUKEMIA & LYMPHOMA (2015)
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes
Talha Badar et al.
LEUKEMIA RESEARCH (2015)
Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia
Manja Meggendorfer et al.
HAEMATOLOGICA (2015)
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
R. Coleman Lindsley et al.
BLOOD (2015)
Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations
Tung-Liang Lin et al.
HAEMATOLOGICA (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis
Jie Jin et al.
PLOS ONE (2014)
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML
K. Takahashi et al.
LEUKEMIA (2013)
Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database
Ofir Shukron et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Mutations affecting mRNAsplicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
Frederik Damm et al.
BLOOD (2012)
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
Felicitas Thol et al.
BLOOD (2012)
The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution
Shang-Ju Wu et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome
Iris Cordoba et al.
CANCER (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients
M. M. Patnaik et al.
LEUKEMIA (2012)
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Timothy A. Graubert et al.
NATURE GENETICS (2012)
Clonal Architecture of Secondary Acute Myeloid Leukemia
Matthew J. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models
Naoko Kato et al.
BLOOD (2011)
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
Luca Malcovati et al.
BLOOD (2011)
WHO-defined 'myelodysplastic syndrome with isolated del(5q)′ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
M. M. Patnaik et al.
LEUKEMIA (2010)
Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia
SBV van Doorn-Khosrovani et al.
ONCOGENE (2005)
Heterogeneous patterns of CEBPα mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia
LY Shih et al.
CLINICAL CANCER RESEARCH (2005)
Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia
LY Shih et al.
LEUKEMIA (2004)
分享论文
